Robert E Widdop Selected Research

Type 2 Angiotensin Receptor

11/2021	Relaxin Attenuates Organ Fibrosis via an Angiotensin Type 2 Receptor Mechanism in Aged Hypertensive Female Rats.
9/2014	Role of inflammation and the angiotensin type 2 receptor in the regulation of arterial pressure during pregnancy in mice.
7/2014	Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
11/2013	Direct AT₂ receptor stimulation is athero-protective and stabilizes plaque in apolipoprotein E-deficient mice.
12/2012	Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats.
8/2012	Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo.
2/2012	Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension.
9/2010	The angiotensin AT2 receptor in left ventricular hypertrophy.
4/2009	Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke.
2/2006	Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert E Widdop Research Topics

Disease

14	Hypertension (High Blood Pressure) 12/2021 - 02/2005
13	Fibrosis (Cirrhosis) 01/2022 - 11/2004
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 08/2003
9	Stroke (Strokes) 01/2022 - 04/2009
9	Atherosclerosis 01/2018 - 08/2003
6	Infarction (Infarctions) 01/2022 - 04/2009
6	Inflammation (Inflammations) 12/2021 - 05/2010
4	Ischemic Stroke 01/2017 - 08/2012
3	Heart Failure 01/2022 - 04/2007
3	Brain Ischemia (Cerebral Ischemia) 01/2017 - 08/2012
3	Hypertrophy 01/2012 - 05/2003
2	Heart Diseases (Heart Disease) 01/2022 - 08/2014
2	Cicatrix (Scar) 01/2022 - 08/2014
2	Chronic Renal Insufficiency 12/2021 - 01/2021
2	Neointima 12/2019 - 08/2003
2	Necrosis 01/2018 - 05/2010
2	Type 2 Diabetes Mellitus (MODY) 01/2018 - 07/2013
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2016 - 01/2015
2	Ischemia 01/2014 - 08/2012
2	Atherosclerotic Plaque (Atheroma) 07/2013 - 09/2008
2	Cardiomegaly (Heart Hypertrophy) 11/2004 - 05/2003
1	Glioblastoma (Glioblastoma Multiforme) 11/2020
1	Hyperplasia 12/2019
1	Cardiomyopathies (Cardiomyopathy) 11/2019
1	Nervous System Diseases (Neurological Disorders) 01/2017
1	Acidosis 01/2017
1	Obesity 01/2016
1	Neoplasms (Cancer) 07/2014
1	Brain Injuries (Brain Injury) 01/2014

Drug/Important Bio-Agent (IBA)

11	Type 2 Angiotensin ReceptorIBA 11/2021 - 03/2005
7	compound 21IBA 01/2017 - 04/2011
6	Pharmaceutical PreparationsIBA 01/2022 - 04/2011
6	RelaxinIBA 11/2021 - 07/2014
5	CGP 42112AIBA 02/2020 - 04/2009
5	AngiotensinsIBA 02/2016 - 04/2008
5	Angiotensin IIIBA 01/2016 - 01/2008
5	Neuroprotective AgentsIBA 07/2014 - 04/2009
4	SaltsIBA 12/2021 - 11/2012
4	Peptides (Polypeptides)IBA 01/2021 - 12/2008
4	candesartan cilexetil (Amias)FDA Link 02/2020 - 05/2003
4	ApolipoproteinsIBA 01/2018 - 01/2008
4	PD 123319IBA 01/2014 - 11/2004
4	Antihypertensive Agents (Antihypertensives)IBA 09/2013 - 02/2005
3	Desoxycorticosterone Acetate (DOCA)FDA Link 12/2021 - 11/2012
3	Perindopril FDA LinkGeneric 01/2021 - 05/2003
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 08/2014
3	Liraglutide FDA Link 01/2016 - 04/2011
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2016 - 04/2011
3	Endothelin-1 (Endothelin 1)IBA 12/2015 - 04/2009
3	nitroxylIBA 09/2013 - 04/2007
3	Apolipoproteins E (ApoE)IBA 07/2013 - 09/2008
2	Coloring Agents (Dyes)IBA 01/2022 - 01/2021
2	salicylhydroxamic acid (SHAM)IBA 01/2021 - 02/2005
2	Acetates (Acetic Acid Esters)FDA Link 01/2021 - 11/2012
2	Desoxycorticosterone (Deoxycorticosterone)IBA 01/2021 - 11/2012
2	human serelaxin proteinIBA 02/2020 - 11/2019
2	Histone Deacetylase InhibitorsIBA 12/2019 - 01/2008
2	Plasminogen InactivatorsIBA 01/2018 - 04/2011
2	Acid Sensing Ion ChannelsIBA 01/2017 - 12/2015
2	AcidsIBA 01/2017 - 12/2015
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 07/2014 - 08/2012
2	CholesterolIBA 05/2010 - 08/2003
2	Biomarkers (Surrogate Marker)IBA 05/2010 - 01/2008
2	Vasodilator Agents (Vasodilators)IBA 04/2008 - 03/2005
1	ThioninsIBA 01/2022
1	Evans Blue (Blue, Evans)FDA Link 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	CollagenIBA 01/2021
1	Antifibrotic AgentsIBA 01/2021
1	QuercetinIBA 11/2020
1	Losartan (Cozaar)FDA LinkGeneric 11/2020
1	4-Aminobenzoic Acid (4 Aminobenzoic Acid)IBA 12/2019
1	candesartanIBA 11/2019
1	Peptide Receptors (Peptide Receptor)IBA 11/2019
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 11/2019
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2018
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2018
1	dapagliflozinIBA 01/2018
1	Sodium-Glucose Transport ProteinsIBA 01/2018
1	Spider Venoms (Venom, Spider)IBA 01/2017
1	DisulfidesIBA 01/2017
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2016
1	GAP-43 Protein (GAP 43 Protein)IBA 01/2016
1	trkB ReceptorIBA 01/2016
1	VenomsIBA 12/2015
1	AVE 0991IBA 01/2015
1	Enalapril FDA LinkGeneric 08/2014
1	Drinking WaterIBA 08/2014
1	Peptide Hormones (Polypeptide Hormones)IBA 08/2014
1	dimemorfan (AT 17)IBA 08/2014
1	Transforming Growth Factors (Transforming Growth Factor)IBA 08/2014
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 08/2014
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 08/2014
1	ReninIBA 07/2014
1	CytokinesIBA 01/2014

Therapy/Procedure

6	Therapeutics 01/2021 - 05/2011
2	Cannula 12/2015 - 04/2009
1	Transplantation 12/2021